CVS vs. CAH: Which Healthcare Services Stock Is the Better Pick Now?

CVS Health is favored over Cardinal Health based on a higher implied analyst upside of 29.55% to a $115.09 average target, versus 21.02% upside to $272.75 for CAH. CVS reported Q2 2026 Health Services revenue growth of 11.5% to $51.8 billion and adjusted operating-income growth of 10% to $1.73 billion, while Cardinal's fiscal 2026 Pharmaceutical and Specialty Solutions revenue rose 15% to $234.8 billion and profit increased 23% to $2.8 billion. Both companies carry Zacks Rank #3 (Hold), with reimbursement, contract, tariff and broader macroeconomic risks remaining key constraints.

Analysis

The apparent CVS valuation discount should not be assessed on price-to-sales: both PBM and distributor revenue are largely pass-through, while CVS carries materially more earnings volatility through Aetna and the still-unproven primary-care asset base. The investable issue over the next 1-3 months is whether Pharmacy Services growth converts to durable operating-margin stability despite 340B changes and client demands for transparent pass-through pricing. If it does, CVS can earn a multiple re-rating from its current “managed-care problem” framing; if not, revenue growth will be discounted as drug-price inflation rather than economic value creation.

CAH's stronger execution is increasingly exposed to a different risk: its distribution model has low incremental margin and concentrated-contract downside. Specialty, nuclear and cell/gene therapy logistics can lift mix over 6-18 months, but that premium is vulnerable if a large customer rebids or if branded-drug volume normalizes. McKesson (MCK) and Cencora (COR) are the more direct read-throughs: a broad specialty-distribution tailwind favors all three, whereas a CAH-specific contract loss would create a relative-value opportunity rather than invalidate the sector thesis.

Consensus likely overweights published analyst target upside and underweights regulatory asymmetry. PBM reform, Medicaid reimbursement pressure, and further 340B policy changes create a discontinuous downside for CVS, while CAH's tariff/freight exposure is more gradual and potentially recoverable through pricing. The contrarian view is that CVS's selective clinic rationalization can be accretive if it stops funding structurally low-return sites; evidence should emerge in Health Care Delivery loss reduction and consolidated cash conversion, not in top-line growth.

Near term, this is a CVS execution trade rather than a broad healthcare-services beta call. Maintain a 6-18 month preference for specialty distribution economics via CAH/MCK/COR only if contract retention and segment-margin progression remain intact; the historical performance gap makes CAH particularly susceptible to a modest guide-down.

Key Decisions for Investors

• Initiate a 1-3 month long CVS / short CAH pair at equal dollar exposure ahead of the next earnings cycle. Thesis: CVS has more room for an earnings-quality re-rating if PBM retention and care-delivery losses improve, while CAH has higher expectations after its relative run. Target 10-15% relative return; exit if CVS cuts full-year operating-income guidance or CAH raises segment-profit guidance materially.
• For lower-beta specialty exposure, prefer long MCK or COR over adding CAH at current momentum. Reassess after CAH discloses major customer renewal status and Pharmaceutical/Specialty segment margin; a material contract renewal at favorable economics would invalidate the CAH underweight.
• Treat CVS as an event-driven watch rather than a standalone core long until management quantifies 340B impact and provides a credible Health Care Delivery profitability bridge. Add only if quarterly operating income and free-cash-flow guidance hold while clinic rationalization reduces losses; a reimbursement-policy adverse ruling is a hard stop.
• Avoid using forward P/S as the primary relative valuation signal for CVS versus CAH. Monitor operating margin, cash conversion, net debt reduction for CVS, and gross-profit dollars per distributed dollar plus contract concentration for CAH; these metrics determine whether either multiple can expand over the next 6-18 months.